Search results for: Value-Based Pricing
Filter search results
Dr. Seán Byrne
3 September 2024
…positions on all legislative and policy files related to medicines’ regulation throughout the product life-cycle. Prior to joining EUCOPE Seán worked in Brussels-based trade associations and consultancies, advising innovative pharmaceutical…
The Effect of Free Personal Care for the Elderly on Informal Caregiving
1 February 2013
…producing a limited net benefit. In this Research Paper, Sarah Karlsberg Schaffer undertakes a comprehensive analysis based on a “natural experiment”: the introduction of free personal care for the elderly…
Malnutrition in the 1960s?
1 July 1967
…and unjustified deductions based on these findings have been published. Only after an examination of all these areas and their inter-relationship can an adequate assessment of nutritional status be made….
Early Diagnosis of Visual Defects
1 July 1967
…based entirely on the reduction of intra-ocular pressure. Detection of the disease is frequently by measurement of this pressure by tonometry, but this presents problems in that it is not…
Is There a Productivity Crisis in Pharmaceutical R&D?
6 January 2012
…changes in both the regulatory and marketing climates. In addition to describing overall trends, Prof Riccaboni also compares the R&D performance of companies based in the US and Europe, and…
Insights From 2022 and Emerging Issues in 2023
7 December 2022, 12:00am
…of health outcomes and where we have got to in including carers’ quality of life in Health Technology evaluations. Innovation, precision and value: Showcasing OHE’s indication-based payment masterclass and demonstrating…
Challenges and Opportunities for Improving Benefit-Risk Assessment of Pharmaceuticals from an Economic Perspective
1 August 2008
…the circumstances in which each could be used. Although such methods can help inform and improve regulatory decision making, these difficult decisions will always require judgments based on multiple considerations….
Medicines, Health and the Poor World
1 April 1982
…allocation in most developing countries was too heavily biased towards urban, hospital based, curative medicine, OHE noted that in many poor countries two thirds to three quarters of public health…
Costs and Benefits of Regulating New Product Development in the UK Pharmaceutical Industry
3 January 1982
…The first concerned prices; this second paper is concerned, by contrast, with the costs of pharmaceutical innovation. This study by Keith Hartley and Alan Maynard is based on a survey…